Herpes Simplex Keratitis Treatment Market

Herpes Simplex Keratitis Treatment Market Snapshot (2023 to 2033)

The anticipated size of the herpes simplex keratitis treatment market in 2022 was USD 4,237.2 million and is estimated to be USD 4,442.2 million in 2023. There are a few key factors that are anticipated to expand the herpes simplex virus treatment market such as:

• Rise in the prevalence of herpes simplex virus infection.
• Increase in the rate of new infections.
• The advancement in the treatment and diagnostic methods.
• Growing government funding.
• Upsurge in the mode of transmission of the infectious disease.

According to the Future Market Insights analysis report, herpes simplex keratitis treatment market is projected to expand at a CAGR of 6.1% between 2023 and 2033, totaling around USD 8,022.9 million by 2033.

The ongoing development of advanced healthcare infrastructures worldwide is likely to augment the demand for herpes simplex keratitis treatment in the assessment period. Herpes simplex virus keratitis is an infection of epithelial cells that are present on the surface of the eye. It also causes retrograde infection of nerves that serve the cornea.

Primary infection usually leads to the swelling of eyelids and the conjunctiva, as well as itchy, white lesions on the corneal surface. Some of the additional symptoms include sinusitis, mild to acute dryness, and dull pain in the eye.

Recurrent infection is often caused by the reactivation of the virus and transportation of the same from the nerve axon to sensory nerve endings. Antiviral treatment either in the form of topical medications or oral administration of famciclovir or valacyclovir for 10 to 14 days is required when keratitis occurs. The condition is diagnosed by a slit-lamp examination. The rising adoption of topical therapy owing to its high efficacy is anticipated to propel the market in the future years.

Attributes	Details
Projected Forecast Value (2022)	USD 4,237.2 million
Projected Forecast Value (2023)	USD 4,442.2 million
Projected Forecast Value (2033)	USD 8,022.9 million
Growth rate	6.1% CAGR
Forecast period	2023 to 2033

Herpes Simplex Keratitis Treatment Market Historical Analysis (2018 to 2022) Vs. Forecast Outlook (2023 to 2033)

Global herpes simplex keratitis treatment market expanded at a CAGR of 3.9% between 2018 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 6.1% between 2023 and 2033.

Therapeutics segment includes valacyclovir drug considerably dominates the market as it is cost-effective, easily available, and effective in blocking the virus from reproducing in the body, thereby having advantages to controlling the symptoms of an outbreak.

Valacyclovir is most widely used for cold sores determinable to its high absorption rate. Efforts and investments are done for providing vaccination for the disease condition which is anticipated to boost the growth of the vaccine segment.

Prominent Drivers Spearheading Herpes Simplex Keratitis Treatment Market Growth

Increasing Research and Development Activities

Increasing research and development activities conducted by numerous key players to launch new drugs are set to propel the market in the near future. The rising cases of herpes simplex virus type 2 and herpes simplex virus type 1 across the globe is another key factor that is estimated to bode well for the herpes simplex keratitis treatment market growth.

According to the World Health Organization (WHO), nearly 3.7 billion people under the age of 50 years have herpes simplex virus type 1 infection across the globe, whereas around 491 million people aged 15 to 49 years have herpes simplex virus type 2 infection. These numbers are set to surge in the upcoming years, thereby propelling the growth in this market.

Challenges Faced by the Herpes Simplex Keratitis Treatment Industry

Cost of Herpes Simplex Keratitis Treatment is High

The cost of herpes simplex keratitis treatment is high. As per a study conducted by a team of researchers at Saint Louis University, Missouri, people in the United States spend tens of millions for the treatment of this condition. Moreover, people, especially in emerging economies may not be able to spend a huge amount and this may hamper the herpes simplex keratitis treatment market growth in the future.

Region-wise Analysis

North America is Emerging as an Opportunistic Herpes Simplex Keratitis Treatment Market

North America is projected to remain at the forefront by procuring the notable herpes simplex keratitis treatment market share of 34.7% in the near future. Further, the increasing prevalence of infections associated with the herpes simplex virus in the United States is a leading factor that is likely to propel the market with a value share of 32%.

Sexually active individuals or those who have had 3 or more sex partners in their lifetime are at a high risk of developing type 1 keratitis.

According to the Centers for Disease Control and Prevention (CDC), 1 in 5 individuals have a Sexually Transmitted Infection (STI), such as genital herpes in the United States, totaling around 68 million infections. In addition to that, new STIs total around USD 16 billion in direct medical costs. This trend is projected to continue throughout the evaluation period, thereby boosting North America’s market.

Asia Pacific is Contributing to the Growth of the Herpes Simplex Keratitis Treatment Market

The growing number of new product launches by reputed companies is expected to fuel the sales of herpes simplex keratitis treatment options in Asia Pacific. The surging number of clinical trials in China, India, and Australia is another significant factor that is estimated to augur well for the market. China is forecasted to expand at a CAGR of 7.8%, whereas India is forecasted to expand at 7.1% CAGR. Australia is forecasted to capture 8.4% CAGR. For example,

A hospital in Ghaziabad, India, reported the first-ever case of herpes simplex virus infection that was termed as ‘very dangerous.’ Doctors discovered that COVID-19-recovered patients who have weak immune systems are most likely to develop this condition. Thus, the rising incidence of life-threatening disorders across Asia Pacific is projected to accelerate the market.

Category-wise Analysis

Acyclovir has a Dominant Share in the Market

Acyclovir has a significant position in the market with a value share of 29.8%. Acyclovir and its analogs, are considered to be the inhibitors of viral DNA replication and are the only approved medicines for HSV that are used for infection therapies.

Topical Route of Distribution Holds a Leading Position in the Market

Topical route of distribution holds a leading position in the market with a value share of 43.8%. Host tissue (cornea) may become effective for HSV infection and repetition with topical, intravitreal, or systemic medications. In humans, recurrent ocular HSV-1 disease has mainly contributed to the usage of prostaglandin agonists, corticosteroids, and inhibitors of angiogenesis.

Market Competition

The global herpes simplex keratitis treatment market contains a large number of big and small players. Some of them include Aurobindo Pharma, GlaxoSmithKline, Cipla, Blistex, Mylan, Vectans Pharma, Dr. Reddy's Laboratories, Bausch Health, Novartis International AG, and Jubilant Cadista among others.

The majority of the leading companies are increasingly focusing on mergers and acquisitions, as well as geographical expansions to gain a competitive edge in the market. Meanwhile, a few other key players are striving to come up with innovative products to fulfill the high unmet needs of patients across the globe.

• In December 2022, Global private equity fund Blackstone’s planned to submit a non-binding bid to acquire the entire 33.47% promoter stake in Cipla, India’s third-largest generics company by revenues, which had sparked a debate over the company’s future.
• In February 2023, Novartis, had mentioned that it is on track to become a pure-play innovative medicines company, uniquely positioned to leverage its global scale and R&D platforms. Its six multi-billion brands5 now represent 32% of our Innovative Medicines sales and are growing 26%.
• Pluvicto and Scemblix had very strong launch performances, and the Leqvio launch continues to progress. Pivotal Ph3 readouts for two iptacopan studies and Pluvicto in earlier lines of therapy provide strong confidence for near to mid-term growth. Looking ahead, we have a catalyst rich pipeline with 15 pivotal readouts in the mid-term. We expect to continue to deliver improved financials and strengthen Novartis ESG foundations, on our journey to become most trusted and valued medicines company in the world”.

Scope of Report

Report Attributes	Details
Growth Rate	CAGR of 6.1% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Drug, Route of Administration, Region
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; South Asia & Pacific; East Asia; The Middle East & Africa
Key Countries Profiled	The United States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, Russia, Poland, Czech Republic, Romania, China, Japan, South Korea, India, Bangladesh, Australia, New Zealand, GCC countries, South Africa, Israel
Key Companies Profiled	GlaxoSmithKline; Vectans Pharma; Blistex; Bausch Health; Aurobindo Pharma; Dr. Reddy's Laboratories; Cipla; Jubilant Cadista; Mylan; Novartis International AG
Customization	Available Upon Request

Key Segments Profiled in the Herpes Simplex Keratitis Treatment Industry Survey

By Drug:

• Famciclovir
• Valacyclovir
• Acyclovir
• Other Drugs

By Route of Administration:

• Topical
• Injection
• Oral

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• South Asia & Pacific
• East Asia
• The Middle East & Africa

Frequently Asked Questions

What is the Recent Market Valuation?

The market is estimated to secure a valuation of USD 4,442.2 million in 2023.

What is the Projected Size of the Market by 2033?

The global market size is expected to reach USD 8,022.9 million by 2033.

What is the Growth Potential of the Market?

The growth potential of the market is 6.1% through 2033.

Which Factor is Helping the Market Advance?

Persistent research and development efforts are helping the market advance.

Which Factor is Derailing the Market Growth?

High cost of herpes simplex keratitis treatment is derailing the market growth.